Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

The Trust Test

- PMLiVE

Repatha’s price tag too rich for UK’s NICE

HTAbody turns the cholesterol-lowering antibody down in draft guidance

- PMLiVE

Janus kinase inhibitors are amongst the most read abstracts at the American College of Rheumatology 2015

Rheumatologists eagerly await trial data for Janus kinase inhibitors

Lucid Group Communications Limited

- PMLiVE

Merck & Co posts positive hepatitis C data

Elbasvir/grazoprevir achieves high cure rates for patients who inject drugs

- PMLiVE

Takeda UK adds to its senior leadership team

Simon Meadowcroft and Pauline Bromley join the firm 

- PMLiVE

FDA deems Merck KGaA and Pfizer’s avelumab a breakthrough

Could become first-in-class treatment for Merkel cell carcinoma

- PMLiVE

AZ sets price of new lung cancer drug Tagrisso

Price tag of $150,000 per year given

- PMLiVE

Crescendo Biologics appoints Dr Kevin Johnson as chairman

Brings Cambridge, UKfirm experience from Pangenetics

Bristol-Myers Squibb (BMS) building

BMS closer to kidney cancer approval for Opdivo

Wins priority review for renal cell carcinoma

- PMLiVE

Merck seeks oasis in CETP inhibitor desert

Pledgesto continue anacetrapib trials despite series of failures in its class

CAR-T cancer therapy passes milestone

Belgianbiotech Celyad's cancer immunotherapy will now be tested at higher doses

- PMLiVE

Mylan misses Perrigo takeover deadline

Failureto take 50% stake ends near-term hopes for a bid

- PMLiVE

J&J gets FDA green light for myeloma drug Darzalex

First-in-classtargeted immunotherapy wins US approval

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links